Overexpression of genes on 16q associated with cisplatin resistance of testicular germ cell tumor cell lines

Testicular germ‐cell tumors (TGCTs) show exquisite sensitivity to cisplatin‐based chemotherapy, and therefore this is considered a good model system for studying the mechanism of chemotherapy resistance. Although the genetic alterations related to TGCT have been well studied, little is known about the genetic basis of chemotherapy resistance, which occurs in a small proportion of TGCTs. In this study, we investigated genomic and expression differences between three cisplatin‐sensitive and their paired cisplatin‐resistant lines using combined whole‐genome screen approaches. Comparative genomic hybridization (CGH) analysis on chromosomes revealed genetic differences between the resistant and parent cell lines in each pair, but did not show any consistent chromosome changes in all three lines. Microarray CGH analysis generated some additional information of DNA copy number gains and losses including some important oncogenes, tumor‐suppressor genes, and drug‐resistance‐related genes. However, no consistent genomic region changes were found in the three cell lines. Interestingly, when comparative expressed sequence hybridization, a technique for gene expression profiling along chromosomes, was applied, we discovered a consistently overexpressed chromosomal region in all three resistant lines compared with their parent lines. The minimum overlapping chromosomal region is at 16q22–23. Further definition of genes in this chromosomal region will aid our understanding of the mechanism of cisplatin resistance and may offer novel therapeutic targets. © 2005 Wiley‐Liss, Inc.

[1]  Alan Horwich,et al.  Testicular germ-cell cancer , 2006, The Lancet.

[2]  C. de Wolf‐Peeters,et al.  Comparative expressed sequence hybridization studies of hairy cell leukemia show uniform expression profile and imprint of spleen signature. , 2004, Blood.

[3]  F. Eyben.  Chromosomes, genes, and development of testicular germ cell tumors , 2004 .

[4]  Javed Khan,et al.  Diagnostic Classification of Cancer Using DNA Microarrays and Artificial Intelligence , 2004, Annals of the New York Academy of Sciences.

[5]  Simon Rogers,et al.  Expression profiling targeting chromosomes for tumor classification and prediction of clinical behavior , 2003, Genes, chromosomes & cancer.

[6]  G. Jakse,et al.  Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors. , 2003, Cancer research.

[7]  Chi-Hung Lin,et al.  Genotypic analysis of esophageal squamous cell carcinoma by molecular cytogenetics and real-time quantitative polymerase chain reaction. , 2003, International journal of oncology.

[8]  N. Nishida,et al.  Chromosomal instability and human hepatocarcinogenesis. , 2003, Histology and histopathology.

[9]  J. Masters,et al.  Curing metastatic cancer: lessons from testicular germ-cell tumours , 2003, Nature Reviews Cancer.

[10]  C. Bokemeyer,et al.  Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  E. D. de Vries,et al.  The attractive Achilles heel of germ cell tumours: an inherent sensitivity to apoptosis‐inducing stimuli , 2003, The Journal of pathology.

[12]  H. Enzan,et al.  Review of papillary renal cell carcinoma with focus on clinical and pathobiological aspects. , 2003, Histology and histopathology.

[13]  R. Huddart,et al.  Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p11.2–p12.1 , 2003, Oncogene.

[14]  Bhuvanesh Singh,et al.  Comprehensive molecular cytogenetic characterization of cervical cancer cell lines , 2003, Genes, chromosomes & cancer.

[15]  C. Bokemeyer,et al.  Molecular determinants of treatment response in human germ cell tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  Z. Onadim,et al.  Comparative genomic hybridization of 49 primary retinoblastoma tumors identifies chromosomal regions associated with histopathology, progression, and patient outcome , 2003, Genes, chromosomes & cancer.

[17]  R. Lothe,et al.  Genetic profiling of colorectal cancer liver metastases by combined comparative genomic hybridization and G‐banding analysis , 2003, Genes, chromosomes & cancer.

[18]  J. Droz,et al.  Growth regulatory factors and signalling proteins in testicular germ cell tumours , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[19]  D. Goudie,et al.  Karyotypic aberrations of chromosomes 16 and 17 are related to survival in patients with breast cancer , 2002, The British journal of surgery.

[20]  Yong-jie Lu,et al.  Chromosome 1q expression profiling and relapse in Wilms' tumour , 2002, The Lancet.

[21]  M. Odero,et al.  Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas , 2002, Histopathology.

[22]  C. Bokemeyer,et al.  Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. , 2002, Cancer research.

[23]  C. Bokemeyer,et al.  Role of P53 and MDM2 in treatment response of human germ cell tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  I. Tomlinson,et al.  Allelic imbalance analysis of chromosome 16q shows that grade I and grade III invasive ductal breast cancers follow different genetic pathways , 2002, The Journal of pathology.

[25]  W. Linehan,et al.  The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. , 2001, Cancer research.

[26]  A. Cleton-Jansen.  E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? , 2001, Breast Cancer Research.

[27]  D Williamson,et al.  Comparative expressed sequence hybridization to chromosomes for tumor classification and identification of genomic regions of differential gene expression , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  C. Bokemeyer,et al.  Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis. , 2000, The American journal of pathology.

[29]  R. Oliver,et al.  Current opinion in germ cell cancer 2000. , 2000, Current opinion in oncology.

[30]  J. Groten,et al.  Role of metallothionein in cisplatin sensitivity of germ‐cell tumours , 2000, International journal of cancer.

[31]  R. Chaganti,et al.  Genetics and biology of adult human male germ cell tumors. , 2000, Cancer research.

[32]  J. Moul,et al.  Molecular Genetic Parameters in Pathogenesis and Prognosis of Testicular Germ Cell Tumors , 2000, European Urology.

[33]  G. Capellá,et al.  DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma. , 2000, Cancer genetics and cytogenetics.

[34]  A. W. Boersma,et al.  Distinct p53‐independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines , 1999, International journal of cancer.

[35]  V. Reuter,et al.  Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. , 1998, Cancer research.

[36]  P. Marynen,et al.  Identification of the critical region of 12p over-representation in testicular germ cell tumors of adolescents and adults , 1998, Oncogene.

[37]  V. Reuter,et al.  Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation , 1998, Oncogene.

[38]  R. Chaganti,et al.  A genetic perspective of male germ cell tumors. , 1998, Seminars in oncology.

[39]  Yong-jie Lu,et al.  Phyllodes tumors of the breast analyzed by comparative genomic hybridization and association of increased 1q copy number with stromal overgrowth and recurrence , 1997 .

[40]  V. Reuter,et al.  Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[41]  Genes, chromosomes & cancer , 1995 .

[42]  R. Chaganti,et al.  The use of tumor markers in germ cell malignancies. , 1994, Hematology/oncology clinics of North America.

[43]  L. Kèlland,et al.  Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. , 1992, Cancer research.

[44]  D. Solter,et al.  Cell line derived from a metastasis of a human testicular germ cell tumor. , 1980, Cancer research.

[45]  F. V. von Eyben.  Chromosomes, genes, and development of testicular germ cell tumors. , 2004, Cancer genetics and cytogenetics.

[46]  R. Verma,et al.  Chromosomal basis of adenocarcinoma of the prostate. , 1999, Cancer investigation.

[47]  R. Knuechel,et al.  Development and characterization of cisplatin-resistant human testicular and bladder tumour cell lines. , 1990, European journal of cancer.